GlassScriptPhysician profile
Tyler Buchanan
NPI 1962985606
$6,297.78
in general payments reported to CMS, 2019-2025
40 companies · $18.20 in 2025
The $18.20 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,497 · 2022: $2,288 · 2023: $1,449 · 2024: $45.97 · 2025: $18.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.81 | 2021-2025 | |
| Ucb, INC. | $547.09 | 2021-2023 | Briviact |
| Neurocrine Biosciences, INC. | $472.43 | 2021-2023 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $462.96 | 2021-2022 | |
| Sk Life Science, INC. | $419.20 | 2021-2023 | |
| Lilly USA, LLC | $285.40 | 2021-2023 | Reyvow, Emgality |
| Jazz Pharmaceuticals INC. | $277.23 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $263.21 | 2022 | |
| Acorda Therapeutics, INC | $256.24 | 2021-2023 | Inbrija |
| Amneal Pharmaceuticals LLC | $243.54 | 2021-2023 | Rytary |
| Biohaven Pharmaceuticals, INC. | $207.21 | 2021 | |
| Biogen, INC. | $175.06 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $168.97 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $167.71 | 2022-2023 | Dysport |
| Kyowa Kirin, INC. | $156.93 | 2021-2023 | Nourianz |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.